Protein From Tick Saliva Studied For Potential Myasthenia Gravis Treatment, St. Louis University Study 3/26/2009
More...
|
Aspreva Pharmaceuticals Corporation (ASPV) Announces Preliminary Results Of Phase III Trial Of CellCept For Myasthenia Gravis; CellCept Fails To Show Effectiveness Against Neuromuscular Disease 10/27/2006
More...
|
Aspreva Pharmaceuticals Corporation (ASPV) Reports Analysis Of Independent Investigator Initiated Trial Of CellCept In Myasthenia Gravis 10/11/2006
More...
|
Sanofi-Aventis (France) (SASY.PA) To Add Liver Warning To Antibiotic Ketek Label 6/30/2006
More...
|
Novartis Pharma Obtains Additional Approval For Its Proprietary Immunosuppressant Neoral 6/16/2006
More...
|
Aspreva Pharmaceuticals Corporation (ASPV) And Roche (RHHBY) Receive Orphan Drug Designation From FDA For Evaluation Of CellCept In Myasthenia Gravis 1/3/2006
More...
|
Aspreva Pharmaceuticals Corporation (ASPV) Announces Completion Of Patient Enrolment In Phase III Clinical Trial For CellCept In Myasthenia Gravis 11/29/2005
More...
|
Debiopharm S.A. And DeveloGen AG Announce Partnering Of Myasthenia Gravis Program 8/16/2005
More...
|
TolerGenics Exclusively Licenses American Red Cross Immune Tolerance Technology 10/27/2004
More...
|
Aspreva Pharmaceuticals Corporation Initiates Phase III Trial With CellCept For Myasthenia Gravis 6/8/2004
More...
|
SAB-Pharma Launches Shortage Product Used As Treatment For Reversing The Effects Of Muscle Relaxants 12/4/2003
More...
|
Muscle Disease Tied To Pregnancy Problems 11/25/2003
More...
|
Ester Neurosciences Ltd. Gets FDA Orphan Drug Status For Myasthenia Gravis 11/24/2003
More...
|